A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2
Rui Shi
1, 2
,
Chao Shan
3
,
Xiaomin Duan
1, 2
,
Zhi-Hai Chen
4
,
Peipei Liu
5
,
Jin-Wen Song
6
,
Tao Song
1, 7, 8
,
Xiaoshan Bi
1, 9
,
Chao Han
1, 2
,
Lianao Wu
9, 10
,
Ge Gao
3
,
Xue Hu
3
,
Yanan Zhang
3
,
Tong Zhou
1, 10
,
Weijin Huang
11
,
William Jun Liu
5
,
Guizhen Wu
5
,
Bo Zhang
3
,
Lan Wang
11
,
Jianxun Qi
10, 12
,
Feng Hui
13
,
Fusheng Wang
6
,
Qihui Wang
1, 10, 12
,
George F. Gao
10
,
Zhiming Yuan
3
,
Jinghua Yan
1, 10, 12
4
7
Shanxi Academy of Advanced Research and Innovation, Taiyuan, China
|
13
Shanghai Junshi Biosciences Co. Ltd, Shanghai, China
|
Тип публикации: Journal Article
Дата публикации: 2020-05-26
scimago Q1
wos Q1
БС1
SJR: 18.288
CiteScore: 78.1
Impact factor: 48.5
ISSN: 00280836, 14764687
PubMed ID:
32454512
Multidisciplinary
Краткое описание
An outbreak of coronavirus disease 2019 (COVID-19)1–3, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)4, has spread globally. Countermeasures are needed to treat and prevent further dissemination of the virus. Here we report the isolation of two specific human monoclonal antibodies (termed CA1 and CB6) from a patient convalescing from COVID-19. CA1 and CB6 demonstrated potent SARS-CoV-2-specific neutralization activity in vitro. In addition, CB6 inhibited infection with SARS-CoV-2 in rhesus monkeys in both prophylactic and treatment settings. We also performed structural studies, which revealed that CB6 recognizes an epitope that overlaps with angiotensin-converting enzyme 2 (ACE2)-binding sites in the SARS-CoV-2 receptor-binding domain, and thereby interferes with virus–receptor interactions by both steric hindrance and direct competition for interface residues. Our results suggest that CB6 deserves further study as a candidate for translation to the clinic. Two monoclonal antibodies isolated from a patient with COVID-19 are shown to interfere with SARS-CoV-2–receptor binding, and one displays potent action against this virus in vitro and in a rhesus macaque model.
Найдено
Ничего не найдено, попробуйте изменить настройки фильтра.
Найдено
Ничего не найдено, попробуйте изменить настройки фильтра.
Топ-30
Журналы
|
10
20
30
40
50
60
70
80
|
|
|
bioRxiv
76 публикаций, 5.93%
|
|
|
Nature Communications
40 публикаций, 3.12%
|
|
|
Frontiers in Immunology
34 публикации, 2.65%
|
|
|
Cell Reports
27 публикаций, 2.11%
|
|
|
Cell
26 публикаций, 2.03%
|
|
|
Vaccines
21 публикация, 1.64%
|
|
|
PLoS Pathogens
19 публикаций, 1.48%
|
|
|
Viruses
18 публикаций, 1.41%
|
|
|
Nature
18 публикаций, 1.41%
|
|
|
International Journal of Molecular Sciences
17 публикаций, 1.33%
|
|
|
Science
16 публикаций, 1.25%
|
|
|
Signal Transduction and Targeted Therapy
15 публикаций, 1.17%
|
|
|
Science Translational Medicine
14 публикаций, 1.09%
|
|
|
Emerging Microbes & Infections
14 публикаций, 1.09%
|
|
|
Scientific Reports
12 публикаций, 0.94%
|
|
|
Cell Host and Microbe
12 публикаций, 0.94%
|
|
|
iScience
10 публикаций, 0.78%
|
|
|
Cell Discovery
10 публикаций, 0.78%
|
|
|
Cell Reports Medicine
10 публикаций, 0.78%
|
|
|
Immunity
10 публикаций, 0.78%
|
|
|
medRxiv : the preprint server for health sciences
10 публикаций, 0.78%
|
|
|
mAbs
9 публикаций, 0.7%
|
|
|
Journal of Virology
9 публикаций, 0.7%
|
|
|
Proceedings of the National Academy of Sciences of the United States of America
9 публикаций, 0.7%
|
|
|
Frontiers in Microbiology
7 публикаций, 0.55%
|
|
|
Communications Biology
7 публикаций, 0.55%
|
|
|
Computational and Structural Biotechnology Journal
7 публикаций, 0.55%
|
|
|
Journal of Molecular Biology
7 публикаций, 0.55%
|
|
|
Microbiology spectrum
7 публикаций, 0.55%
|
|
|
10
20
30
40
50
60
70
80
|
Издатели
|
50
100
150
200
250
300
|
|
|
Cold Spring Harbor Laboratory
283 публикации, 22.09%
|
|
|
Elsevier
257 публикаций, 20.06%
|
|
|
Springer Nature
209 публикаций, 16.32%
|
|
|
MDPI
96 публикаций, 7.49%
|
|
|
Frontiers Media S.A.
64 публикации, 5%
|
|
|
Wiley
51 публикация, 3.98%
|
|
|
American Chemical Society (ACS)
47 публикаций, 3.67%
|
|
|
Taylor & Francis
41 публикация, 3.2%
|
|
|
American Association for the Advancement of Science (AAAS)
35 публикаций, 2.73%
|
|
|
Oxford University Press
32 публикации, 2.5%
|
|
|
American Society for Microbiology
30 публикаций, 2.34%
|
|
|
Public Library of Science (PLoS)
28 публикаций, 2.19%
|
|
|
Proceedings of the National Academy of Sciences (PNAS)
9 публикаций, 0.7%
|
|
|
Royal Society of Chemistry (RSC)
8 публикаций, 0.62%
|
|
|
Rockefeller University Press
7 публикаций, 0.55%
|
|
|
American Society for Clinical Investigation
5 публикаций, 0.39%
|
|
|
American Society for Biochemistry and Molecular Biology
5 публикаций, 0.39%
|
|
|
Social Science Electronic Publishing
5 публикаций, 0.39%
|
|
|
Spandidos Publications
4 публикации, 0.31%
|
|
|
European Molecular Biology Organization
4 публикации, 0.31%
|
|
|
Bentham Science Publishers Ltd.
3 публикации, 0.23%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
3 публикации, 0.23%
|
|
|
Massachusetts Medical Society
2 публикации, 0.16%
|
|
|
The American Association of Immunologists
2 публикации, 0.16%
|
|
|
Mary Ann Liebert
2 публикации, 0.16%
|
|
|
SAGE
2 публикации, 0.16%
|
|
|
Hindawi Limited
2 публикации, 0.16%
|
|
|
Annual Reviews
2 публикации, 0.16%
|
|
|
IntechOpen
2 публикации, 0.16%
|
|
|
50
100
150
200
250
300
|
- Мы не учитываем публикации, у которых нет DOI.
- Статистика публикаций обновляется еженедельно.
Вы ученый?
Создайте профиль, чтобы получать персональные рекомендации коллег, конференций и новых статей.
Метрики
1.3k
Всего цитирований:
1282
Цитирований c 2024:
145
(11.32%)
Цитировать
ГОСТ |
RIS |
BibTex |
MLA
Цитировать
ГОСТ
Скопировать
Shi R. et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2 // Nature. 2020. Vol. 584. No. 7819. pp. 120-124.
ГОСТ со всеми авторами (до 50)
Скопировать
Shi R., Shan C., Duan X., Chen Z., Liu P., Song J., Song T., Bi X., Han C., Wu L., Gao G., Hu X., Zhang Y., Zhou T., Huang W., Liu W. J., Wu G., Zhang B., Wang L., Qi J., Hui F., Wang F., Wang Q., Gao G. F., Yuan Z., Yan J. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2 // Nature. 2020. Vol. 584. No. 7819. pp. 120-124.
Цитировать
RIS
Скопировать
TY - JOUR
DO - 10.1038/s41586-020-2381-y
UR - https://doi.org/10.1038/s41586-020-2381-y
TI - A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2
T2 - Nature
AU - Shi, Rui
AU - Shan, Chao
AU - Duan, Xiaomin
AU - Chen, Zhi-Hai
AU - Liu, Peipei
AU - Song, Jin-Wen
AU - Song, Tao
AU - Bi, Xiaoshan
AU - Han, Chao
AU - Wu, Lianao
AU - Gao, Ge
AU - Hu, Xue
AU - Zhang, Yanan
AU - Zhou, Tong
AU - Huang, Weijin
AU - Liu, William Jun
AU - Wu, Guizhen
AU - Zhang, Bo
AU - Wang, Lan
AU - Qi, Jianxun
AU - Hui, Feng
AU - Wang, Fusheng
AU - Wang, Qihui
AU - Gao, George F.
AU - Yuan, Zhiming
AU - Yan, Jinghua
PY - 2020
DA - 2020/05/26
PB - Springer Nature
SP - 120-124
IS - 7819
VL - 584
PMID - 32454512
SN - 0028-0836
SN - 1476-4687
ER -
Цитировать
BibTex (до 50 авторов)
Скопировать
@article{2020_Shi,
author = {Rui Shi and Chao Shan and Xiaomin Duan and Zhi-Hai Chen and Peipei Liu and Jin-Wen Song and Tao Song and Xiaoshan Bi and Chao Han and Lianao Wu and Ge Gao and Xue Hu and Yanan Zhang and Tong Zhou and Weijin Huang and William Jun Liu and Guizhen Wu and Bo Zhang and Lan Wang and Jianxun Qi and Feng Hui and Fusheng Wang and Qihui Wang and George F. Gao and Zhiming Yuan and Jinghua Yan},
title = {A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2},
journal = {Nature},
year = {2020},
volume = {584},
publisher = {Springer Nature},
month = {may},
url = {https://doi.org/10.1038/s41586-020-2381-y},
number = {7819},
pages = {120--124},
doi = {10.1038/s41586-020-2381-y}
}
Цитировать
MLA
Скопировать
Shi, Rui, et al. “A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2.” Nature, vol. 584, no. 7819, May. 2020, pp. 120-124. https://doi.org/10.1038/s41586-020-2381-y.